Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Coronavirus Infection Clinical Trial

Official title:

A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04355676
• Other study ID #: XPORT-CoV-1002
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 30, 2020
• Est. completion date: August 30, 2020

Study information

• Verified date: January 2023
• Source: Karyopharm Therapeutics Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 30, 2020
• Est. primary completion date: August 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed laboratory diagnosis of SARS-CoV2 by standard approved reverse transcription polymerase chain reaction (RT-PCR) assay or equivalent approved testing (by local labs).

• Currently hospitalized and consented within the first 48 hours of hospitalization.

• Informed consent provided as above (patients must be dosed with study drug within 12 hours of consent).

• Has symptoms of moderate or severe COVID-19 as demonstrated by:

Moderate COVID-19:

1. Currently hospitalized and requiring medical care for COVID-19, and

2. Peripheral capillary oxygen saturation (SpO2, pulse oximetry) > 94% on room air at screening, and

3. Radiographic evidence of pulmonary infiltrates

Severe COVID-19:

1. At least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress AND

2. Clinical signs indicative of lower respiratory infection with COVID-19, with at least one of the following: respiratory rate = 30 breaths/minute (min), heart rate = 125/min, Oxygen saturation (SpO2) <93% on room air or requires > 2L/minute oxygen by NC in order to maintain SaO2 =93%, PaO2/FiO2 <300 millimeter per mercury (mm/hg)

• Female patients of childbearing potential must have a negative serum pregnancy test at Screening and must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.

• Males who are sexually active must commit to use a highly effective method of contraception while receiving selinexor and for 3 months after the last selinexor dose, or consent to total sexual abstinence (abstinence must occur from enrollment and continue for 3 months after the last selinexor dose).

Exclusion Criteria:

• Evidence of critical COVID-19 based on:

1. Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations)

2. Septic shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg)

3. Multiple organ dysfunction/failure

• In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours

• Concurrent anti-viral and/or anti-inflammatory agents (e.g., biologics, hydroxychloroquine) are not permitted.

• Inadequate hematologic parameters as indicated by the following labs:

1. Patients with severe neutropenia (ANC <1,000 x 10^9/liter [L]) or

2. Thrombocytopenia (e.g., platelets <100,000 per microliter of blood)

• Inadequate renal function as indicated by creatinine clearance (CrCl) <20 milliliter per minute (mL/min) using the formula of Cockcroft and Gault.

• Inadequate hepatic function defined as AST or ALT > 5x the upper limit of normal OR serum direct bilirubin > 2.5x the upper limit of normal.

• Hyponatremia defined as sodium < 135 milliequivalents per liter (mEq/L).

• In the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight.

• Unable to take oral medication when informed consent is obtained.

• Patients with a legal guardian or who are incarcerated.

• Pregnant and breastfeeding women.

Related Conditions & MeSH terms

• Coronavirus Infection
• Coronavirus Infections
• COVID-19

Intervention

Drug:
• Selinexor
20 mg selinexor oral tablet.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Karyopharm Therapeutics Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale		Baseline to Day 14
Secondary	Time to Clinical Improvement (TTCI)		Up to Day 28
Secondary	Overall Death Rate		Day 14, Day 28
Secondary	Rate of Mechanical Ventilation		Up to Day 28
Secondary	Time to Mechanical Ventilation		Up to Day 28
Secondary	Overall Survival		Up to Day 28
Secondary	Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale		Up to Day 28
Secondary	Time to Intensive Care Unit (ICU) Admission		Up to Day 28
Secondary	Rate of Intensive Care Unit (ICU) Admission		Up to Day 28
Secondary	Length of Stay in Hospital		Up to Day 28
Secondary	Percentage of Participants Discharged From Hospital		Up to Day 28
Secondary	Length of Stay in Intensive Care Unit (ICU)		Up to Day 28
Secondary	Duration of Oxygen Supplementation		Up to Day 28
Secondary	Duration of Mechanical Ventilation		Up to Day 28
Secondary	Time to Clinical Improvement in Participants = 70 Years Old		Up to Day 28
Secondary	Time to Clinical Improvement in Participants > 70 Years Old		Up to Day 28
Secondary	Time to Clinical Improvement in Participants with Pre-existing Diseases		Up to Day 28
Secondary	Change in Oxygenation Index		Up to Day 28
Secondary	Time to Improvement of One Point Using WHO Ordinal Scale Improvement		Up to Day 28
Secondary	Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point		Up to Day 28
Secondary	Change from Baseline in C-reactive protein (CRP) Levels		Up to Day 28
Secondary	Change from Baseline in Ferritin Levels		Up to Day 28
Secondary	Change from Baseline in Lactate Dehydrogenase (LDH) Levels		Up to Day 28
Secondary	Number of Participants with Adverse Events (AE)		From start of study drug administration up to follow-up (Day 30)